29 results about "Arterial thrombus" patented technology

The invention relates to a collateral-dredging thrombus-removing traditional Chinese medicine composition for preventing and treating stroke, vascular thrombus, arteriosclerosis, coronary heart disease or waist and leg pain. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 12-65 parts of cooked rhubarb, 10-72 parts of salvia miltiorrhiza, 12-65 parts of cortex moutan, 6-57 parts of rhizoma zingiberis, 8-50 parts of pseudo-ginseng, 15-45 parts of obscured homalomena rhizome, 10-68 parts of leech, 7-76 parts of earthworm, 15-70 parts of ligusticum wallichii, 6-52 parts of Tibetan capillary artemisia, 7-49 parts of cape jasmine, 3-25 parts of borneol, 6-75 parts of angelica sinensis, 12-65 parts of ginseng, 7-53 parts of pogostemon cablin and 10-77 parts of radix curcumae. The medicine has the effects of promoting blood circulation, removing blood stasis, dredging collaterals and removing thrombus. The traditional Chinese medicine composition can be used for preparing medicines for treating cerebral apoplexy, coronary heart disease, arteriosclerosis and static artery thrombosis diseases, or medicines for soothing channels, activating collaterals and promoting blood circulation to remove blood stasis, which are related to waist and leg pain diseases. The invention provides a prevention and treatment effective solution for people with stroke, vascular thrombosis, arteriosclerosis, coronary heart disease or waist and leg pain.

The present invention discloses a ternary nano self-assembly particle that responds to and regulates the microenvironment of arterial thrombosis and a preparation method thereof. The ternary nano self-assembly particle uses asymmetric zinc phthalocyanine as a template and is self-assembled with a natural small molecule compound containing a para-benzoquinone mother core and a flavonoid compound through hydrophobic interaction, π-π interaction, and electrostatic interaction. The self-assembly nanoparticles provided by the present invention can adsorb plasma proteins in situ in the circulation of the organism and form a protein corona of multiple plasma protein components on the surface; and it can respond to the shear force that increases sharply at the arterial thrombosis site to achieve passive targeting and fixed-point release; in addition, the self-assembly nanoparticles can regulate the arterial thrombosis microenvironment by inhibiting the NF-κB signaling pathway, inhibiting the formation of neutrophil extracellular traps, inhibiting glycolysis, and promoting the cGMP-mediated signaling pathway, thereby significantly improving the prognosis of carotid thrombotic diseases. It also has good biosafety and provides a new nano-therapeutic drug for arterial thrombosis.

The invention discloses a pulmonary artery thrombus aspiration catheter and a manufacturing method thereof, and belongs to the technical field of medical instruments. The pulmonary artery thrombus aspiration catheter comprises a catheter body, a catheter head end and a skirt structure, the catheter head end is in a dome shape and arranged at the far end of the catheter body, the catheter head end has flexibility, and a pre-incision is formed in the top of the far end; the skirt edge structure comprises a self-expansion framework and a covering film arranged on the peripheral side of the self-expansion framework, the self-expansion framework has elasticity, and the self-expansion framework can be restrained and folded in the radial direction and can be automatically unfolded in the radial direction to be in a horn mouth shape after being restrained; the near end of the self-expanding skeleton is connected to the catheter body, the far end of the skirt structure is located in the catheter head end when folded, and the pre-incision is closed; when the far end of the skirt structure is unfolded, the catheter head end can be opened, the pre-incision is opened, at least two valve leaflets are formed, the far end edge of the pre-incision does not exceed the far end edge of the skirt structure, a gap is formed between the adjacent valve leaflets and the skirt structure, and damage to the tricuspid valve and other parts can be reduced.

The invention relates to an F base modified von Willebrand factor vWF targeting aptamer and an application of the F base modified von Willebrand factor vWF targeting aptamer. Specifically, the invention provides an F base modified vWF targeting aptamer (AF-BT100), the F base modified vWF targeting aptamer comprises a nucleotide core sequence as shown in SEQ ID NO: 1, and the 5'end and the 3 'end are respectively connected with at least two artificial hydrophobic F bases. The invention also comprises a radionuclide-labeled molecular imaging probe [68Ga] Ga-NOTA-AF-BT100, which can realize specific PET imaging in the focus of atherosclerosis, carotid artery thrombosis and acute myocardial infarction. According to the invention, the integrated application of diagnosis and treatment of the pantovascular diseases based on the same vWF targeting aptamer is realized for the first time, and a new strategy is provided for accurate diagnosis and treatment of the pantovascular diseases.

Disclosed are methods and compositions for treating or preventing arterial thrombosis in a subject in need thereof comprising administering to the subject a thiol or selenium containing compound.

The invention relates to the field of traditional Chinese medicines, and discloses radix tetrastigme polysaccharide, a preparation method thereof and application of the radix tetrastigme polysaccharide in preparation of antithrombotic drugs. The novel acid glucuronic acid galactomannan (THP5) is extracted from the overground part of the radix tetrastigme polysaccharide for the first time, it is found that the novel acid glucuronic acid galactomannan (THP5) can be used for preventing and treating thrombus diseases including arterial thrombosis, venous thrombosis and the like in a multi-target mode, the application range of the radix tetrastigme polysaccharide is widened, and a new way is provided for treating the thrombus diseases.

The utility model belongs to the technical field of double-cavity visual catheters, and particularly relates to a double-cavity visual catheter for artery thrombus extraction, which comprises a catheter main body, an operation cavity is arranged in the catheter main body, the side wall of the catheter main body is fixedly connected with an operation cavity outer tube, and one end of the operation cavity outer tube far away from the catheter main body is provided with a control assembly. The control assembly comprises a control body, the control body is fixedly connected to the side wall of the guide pipe body, a circulation groove is formed in the control body, a spring groove is formed in the control body, a spring is fixedly connected to the inner wall of the spring groove, one end of the spring is fixedly connected with a moving block, and a clamping pin is fixedly connected to the side wall of the moving block. The medicine suction device is reasonable in structure, medicine can be effectively prevented from flowing out when the suction device is replaced, and the adjacent moving blocks are matched with the sealing gaskets so that the medicine can be well intercepted.

This invention belongs to the field of biomedicine and relates to a procoagulant polypeptide TPTX and its applications. The procoagulant polypeptide TPTX of this invention can exert its procoagulant and hemostatic effects by specifically inhibiting plasmin activity. Experiments have shown that TPTX exhibits significant dose-dependent procoagulant and hemostatic effects in ferric chloride-induced mouse carotid artery thrombosis models, mouse liver hemorrhage models, mouse tail hemorrhage models, and mouse saphenous vein hemorrhage models, with effects superior to the positive control drug 6-aminocaproic acid. Simultaneously, TPTX can reduce the area of ​​atorvastatin-induced cerebral hemorrhage in zebrafish and improve their motor dysfunction. Mechanistic studies show that TPTX has an inhibitory constant Ki of 17.76 nM on plasmin and has no significant effect on the activity of seven other key serine proteases in the coagulation system, demonstrating a clear target and high selectivity. The procoagulant polypeptide of this invention can be used to prepare hemostatic drugs, possessing the advantages of high efficiency, clear target, and high selectivity, with broad prospects for clinical application.

The invention discloses a medicine for treating arterial venous thrombosis obliterans of lower limbs and a preparation method of the medicine. The problem that an existing treatment means is low in cure rate is solved. The medicine is prepared from 21.85 g to 21.90 g of potassium nitrate, 24.95 g to 25.05 g of alumen, four croton seeds, 6.20 g to 6.30 g of mercury and 0.009 g to 0.011 g of white cast iron. The preparation method comprises the following steps: flatly spreading the raw materials on a heat-resistant container with a condensation cover (with a gap of 2-3cm reserved), heating for 9-11 minutes by soft fire at the temperature of 50-80 DEG C to evaporate water, heating for 19-21 minutes by big fire at the temperature of 120-150 DEG C to sublimate and desublimate the active ingredients, cooling, and filling into capsules. The cure rate of the medicine for treating lower limb arterial thrombosis obliterans is 95%, the cure rate of venous thrombosis obliterans is 90%, the preparation process is simple, the activity of effective components can be reserved, and the medicine is suitable for clinical treatment.

The invention relates to an application of a patent medicine Tenapanor approved by FDA in preparing a medicament for resisting platelet and arterial thrombosis. The medicament can be used for effectively inhibiting platelet activation and aggregation and arterial thrombosis block formation. The invention relates to an FDA approved patent medicine Tanipanol capable of effectively inhibiting platelet activation and aggregation induced by a natural agonist ADP and carotid artery and mesenteric artery thrombosis. Tanipamox is used as a novel candidate drug for resisting formation of platelets and arterial thrombosis blocks in fundamental research of thrombotic diseases, and has potential application value in prevention and treatment of arterial thrombosis related diseases.

The application discloses four kinds of tetra-cyclic compounds with selective adenosine diphosphate inhibition, which have the following formula structure, wherein the amino acids represented by AA are L-Ser residues, L-Glu residues, L-Lys residues and L-Tyr residues respectively, the application discloses a preparation method of the tetra-cyclic compounds and application of the tetra-cyclic compounds in treating arterial thrombosis diseases. Experiments prove that the adenosine diphosphate selective inhibitor has good anti-arterial thrombosis effect. Thus, the application provides an effective technical means for resisting arterial thrombosis.

The application relates to a polypeptide functionalized gold nanocluster targeting neutrophils, a preparation method thereof and application thereof in preparation of an anti-thrombus drug, and belongs to the field of biomedical nanomaterials. The nanocluster is formed by Au-S coordination self-assembly of a thiol-containing targeting polypeptide and gold atoms. The polypeptide can specifically recognize neutrophil elastase (NE), realizes targeting of activated neutrophils and inhibits enzyme activity of the neutrophils. The nanocluster inhibits formation of neutrophil extracellular traps (NETs) induced by phorbol ester (PMA) or activated platelets, and shows reduction of histone citrullination (CitH3) level, extracellular DNA release and active oxygen (ROS) generation. In-vivo experiments show that the gold nanocluster is enriched at a thrombus site, and significantly reduces thrombus load in a deep vein thrombosis model and an FeCl3-induced arterial thrombosis model. The application plays an anti-thrombus role by inhibiting NETs.

The present invention discloses a tetramer of Ala-Gln-Gly, namely [Ala-Gln-Gly]<subgt;4< / subgt;, and further discloses a preparation method of the tetramer of Ala-Gln-Gly and its application in the treatment of arterial thrombotic diseases. Experiments have proved that the tetramer of Ala-Gln-Gly of the present invention has excellent anti-arterial thrombosis effect, and its anti-arterial thrombosis effect is significantly stronger than that of Ala-Gln-Gly. Therefore, it is proposed that the present invention provides an effective technical means for anti-arterial thrombosis.

The invention belongs to the technical field of foreign matter capturing, and discloses a capturing device for recovering foreign matter, plaque and embolus in vascular intervention, which comprises a tube body, the end part of the tube body is movably connected with a conical top cover through an adjusting assembly, and a rubber sealing sleeve is fixedly mounted on the side wall, close to the tube body, of the conical top cover in an adhesion manner; the rubber sealing sleeve is of an annular structure, a filling groove is formed in the rubber sealing sleeve, the conical top cover, the first small hole, the filling groove and the like are arranged, during use, the front end of the conical top cover extrudes and penetrates through arterial thrombosis, then clear water is injected into the connecting pipe, and the connecting pipe is sealed; water flow passes through the connecting pipe, passes through the first small hole, the second small hole and the third small hole to enter the connecting groove and then gradually enters the filling groove, the rubber sleeve gradually collides and expands to seal the front end of the thrombus, and during use, the connecting pipe is driven to rotate by rotating the pipe body, so that the first small hole and the third small hole are staggered, and the thrombus can be conveniently filled. And subsequent operation can be carried out.

The invention provides a lower limb artery thrombus removing device and a handle. A guide wire of a mechanism is arranged in a first catheter in a penetrating mode, the first catheter is arranged in a second catheter in a penetrating mode, the second catheter is arranged in a third catheter in a penetrating mode, and the third catheter is arranged in a fourth catheter in a penetrating mode; comprising a balloon which is fixedly arranged on the front portion of the outer wall of the third catheter, and an injection cavity is communicated with the interior of the balloon; comprising a first umbrella-shaped net and first connecting rods, the first connecting rods are evenly distributed around the axis of the first umbrella-shaped net, one ends of the first connecting rods are hinged to the inner side of the first umbrella-shaped net, and the other ends of the first connecting rods are hinged to the second guide pipe; a suction cavity is formed in the tube wall of the fourth catheter, and the front end of the suction cavity is communicated with the outside. The falling thrombus is captured through the umbrella-shaped net, re-embolism caused when the thrombus falls into the far end of the artery is avoided, and meanwhile the thrombus capturing device has the advantages of avoiding erythrocyte lysis caused by thrombus cutting, being high in trafficability, low in cost and the like.

The application discloses four kinds of tetra-cyclic compounds of four amino acids which selectively inhibit arachidonic acid (AA), and discloses a preparation method of the tetra-cyclic compounds and application of the tetra-cyclic compounds in treating arterial thrombosis diseases. Experiments prove that the arachidonic acid selective inhibitor has good anti-arterial thrombosis effect. Thus, the application provides an effective technical means for resisting arterial thrombosis.

The invention provides a multi-modal information fusion method and system for liver transplantation hepatic artery thrombus prediction, and the method comprises the following steps: constructing a multi-modal data joint prediction model based on multi-modal image features and clinical pathological features; and predicting the liver transplantation hepatic artery thrombus by using the multi-modal data combined prediction model. According to the technical scheme, the weight vector of the feature map is generated by using the improved long-short term memory network, and an attention mechanism is introduced through the design of the weight vector, so that multi-modal information can be fused at a higher dimension, and the accuracy of the prediction model is improved.

The invention discloses an ozagrel-RGDF tetramer with the following structural formula, namely [ozagrel-RGDF] 4, and discloses a preparation method of the ozagrel-RGDF tetramer and application of the ozagrel-RGDF tetramer to treatment of arterial thrombotic diseases. Experiments prove that the [ozagrel-RGDF] 4 disclosed by the invention not only has a good anti-arterial thrombosis effect, but also has no bleeding side effect. Therefore, the invention provides a safe and effective technical means for arterial thrombosis resistance.

The utility model relates to the technical field of medical instruments, and provides an arterial thrombus protection device and an embolism system. The filtering piece comprises a shape memory skeleton and a woven net film which is arranged on the shape memory skeleton and is used for intercepting thrombus; the two ends of the shape memory framework are closed up through the first annular piece and the second annular piece correspondingly. The first annular piece fixedly sleeves the guide wire, and the second annular piece slidably sleeves the guide wire; one end of the traction wire is connected with the second annular piece, and the other end is in vitro. According to the arterial thrombus protection device, the filtering piece can be adjusted in a self-adaptive mode according to the size of a blood vessel, the filtering piece can be better attached to the blood vessel, and therefore the effect of capturing fallen plaques or thrombus is improved, and the risk of an operation is reduced; and moreover, the position movement of the filtering piece caused by the length change of the guide wire placed in the body can be avoided, and the operation effect and safety are ensured.

The invention relates to the field of molecular biology and biological medicine, and particularly discloses an antithrombotic effect of Meteorin protein or gene. Experiments prove that after Meteorin protein is incubated, the platelet aggregation reaction can be remarkably inhibited, the platelet spreading area can be reduced, blood clot contraction can be delayed, and meanwhile ATP release and alpha particle release of platelets and activation of surface integrin alpha IIb beta 3 can be inhibited. In a whole thrombus experiment, the Meteorin protein can effectively inhibit the formation of arterial thrombosis. The Meteorin protein is a human endogenous protein, so that the Meteorin protein has relatively small side effects, has relatively high safety as a potential drug, and has a good industrialization prospect.

The invention discloses a biomarker for auxiliary diagnosis of SLE (systemic lupus erythematosus) and application of the biomarker, and belongs to the technical field of biology. The invention discloses one of an anti-NPM1 antibody, an anti-RPLP2 antibody and an anti-MX1 antibody or a combination of any two or three of the anti-NPM1 antibody, the anti-RPLP2 antibody and the anti-MX1 antibody, which can be used as a biomarker for auxiliary diagnosis of SLE. And the kit can be used for auxiliary monitoring of SLE disease activity and auxiliary diagnosis of SLE (combined anti-phospholipid antibody) with clinical phenotypes of arterial thrombosis, microangiopathy, heart valve enuresis and thrombocytopenia, and has good diagnosis efficiency.

An application of a prolyl hydroxylase domain 2 (PHD2) in preparation of drugs for prevention and treatment of platelet thrombus is provided and relates to the field of biomedical technology. The important role of PHD2 protein in the process of platelet adhesion and thrombus formation is provided, PHD2 as a regulatory target of platelet adhesion is also provided, and thrombus formation can be significantly inhibited by knocking down PHD2 gene expression. This provides new technological ways for the development of drugs for antiplatelet thrombus and the improvement of blood microcirculation disorders. The PHD2 inhibitor can inhibit platelet thrombus by inhibiting PHD2, thereby providing new therapeutic options and candidate drugs for the prevention and / or treatment of platelet thrombus diseases due to platelet excessive activation (including, but not limited to arterial thrombosis, such as heart attack and stroke, and venous thrombus diseases, such as pulmonary embolism and deep vein thrombosis).

The invention discloses a lower limb arterial thrombus aspiration device, and belongs to the technical field of medical instruments, the lower limb arterial thrombus aspiration device comprises a catheter assembly, a far-end execution assembly, a thrombus aspiration assembly and a control handle, the catheter assembly is formed by sleeving a guide wire, a transmission catheter and a protective sheath tube in a layered manner, and an expansion net is arranged at the front end of the transmission catheter; the far-end execution assembly comprises a suction pipe and a linkage cutting pipe, the front end of the suction pipe is provided with a conical tip and symmetrical suction holes, and a spiral tool bit at the front end of the linkage cutting pipe is contained in the conical tip. According to the thrombus suction assembly, multi-channel cooperation is achieved through a three-way pipe, a power transmission structure in a control handle drives a linkage cutting pipe to rotate at a constant speed, thrombus grabbing, cutting and suction integrated cooperative operation is achieved, the removing efficiency of various thrombus is improved, thrombus fragment escape is avoided, and the blood vessel scratching and complication risks are reduced.

The present application belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to an antithrombotic polypeptide PM4 and application thereof. The present application is based on an original polypeptide obtained from a transcriptome of a leech salivary gland and an amino acid fragment cut from the original polypeptide, increases {d-Phe}-PRP at an N terminal of the cut amino acid fragment through a synthesis strategy of a hirudin analogue drug bivalirudin, and finally connects the {d-Phe}-PRP and the cut amino acid fragment through a connecting polypeptide to obtain the antithrombotic polypeptide PM4. The antithrombotic polypeptide PM4 can inhibit the activity of thrombin, has a small risk of bleeding, a shorter half-life in the body, higher safety, and significant resistance to thrombosis including arterial thrombosis. Meanwhile, the sequence of the antithrombotic polypeptide PM4 is shorter than the original sequence and is easier to synthesize.

The external Chinese herbal medicine essential oil combined liquid medicine is characterized by being prepared from the following Chinese herbal medicine essential oil: rhizoma arisaematis, radix zanthoxyli, semen strychni, radix aconiti carmichaeli, herba ephedrae, kadsura pepper stem, rhizoma corydalis, pogostemon cablin, ligusticum wallichii, ginger, radix cynanchi paniculati, artemisia anomala, radix angelicae, melissa officinalis, cinnamon, mint and safflower carthamus. The traditional Chinese medicine has the effects of relaxing tendons and activating collaterals, promoting blood circulation to remove blood stasis and relieving swelling and pain; the traditional Chinese medicine composition has the effects of being high in medicine efficacy permeability, rapid in effect taking and capable of rapidly relieving the illness state, and can be used for preparing external application for treating diabetic eye diseases and heart diseases such as heart diseases, coronary heart diseases, heart discomfort or pain, stuffiness pain, angina pectoris, neck arteriosclerosis, plaques and static arterial thrombosis in cardiovascular and cerebrovascular diseases. The external medicine is used for relieving swelling and pain, soothing channels and activating collaterals, and promoting blood circulation to remove blood stasis. The invention provides a convenient, rapid and effective external medicine treatment mode for patients with the diseases.

The invention discloses a novel arterial thrombus thrombolysis catheter and an application method thereof.The left side and the right side of an I-shaped bearing block are each fixedly provided with a handrail, and the bottoms of the two handrails are fixedly connected with the tops of the adjacent extending cross rods through a plurality of springs. According to the novel arterial thrombus thrombolysis catheter and the application method thereof, through mutual cooperation of the guide hose, the connecting sleeve frame, the position adjusting chute and the extrusion roller, the position of the extrusion roller is adjusted, the extrusion degree of the extrusion roller on the guide hose is changed, airflow passing through the guide hose is changed, then the suction force is controlled, thrombus is better sucked, and the thrombus thrombolysis effect is improved. The self-expanding thrombus suction tube is simple in structure and convenient to use, thrombus rupture or falling caused by too large or too small suction force is avoided, blood can flow out again through meshes in the self-expanding filter screen through mutual cooperation of the tube head, the suction cavity, the self-expanding filter screen and the inner connection catheter, blood supply is guaranteed, and thrombus filtration is achieved.

An explainable artificial intelligence system for early prediction of missed severe diagnoses in intensive care unit patients is provided. The system comprises a data processing module configured to receive and process electronic health record data including patient demographics, vital signs, laboratory results, and diagnostic codes. A machine learning module with ensemble, deep learning, and large language models analyzes processed data to predict likelihood of severe diagnoses including acute myocardial infarction, acute pulmonary embolism, bacterial pneumonia, aortic dissection, meningitis, spinal abscess, bacterial endocarditis, and arterial thromboembolism. An explainability module generates feature importance rankings and provides interpretable explanations for predictions.

The invention discloses an ozagrel-RGDS dimer with the following structural formula, namely [ozagrel-RGDS] 2, and discloses a preparation method of the ozagrel-RGDS dimer and application of the ozagrel-RGDS dimer in preparation of antithrombotic drugs. Experiments prove that the [ozagrel-RGDS] 2 disclosed by the invention not only has good anti-arterial thrombosis effect and anti-venous thrombosis effect, but also has no bleeding side effect. Therefore, the invention provides a safe and effective technical means for preparing antithrombotic drugs.